Lessening Organ Dysfunction With VITamin C - COVID-19

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in hospitalized COVID-19 patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université de Sherbrooke
• Collaborator: Lotte & John Hecht Memorial Foundation
• Treatments: Ascorbic Acid

Criteria

Inclusion Criteria:

• Confirmed diagnosis of COVID-19;

• Admitted to hospital (ward or intensive care unit).

Exclusion Criteria:

• Receiving or has received vasopressors during the current hospitalization;

• More than 24 hours has elapsed since receipt of non-invasive ventilatory support (high-flow nasal cannula or continuous positive airway pressure or non-invasive ventilation) or invasive mechanical ventilation;

• Patient is expected to be discharged from the hospital in the next 24 hours;

• More than 14 days have elapsed since the commencement of hospital admission with respiratory illness;

• Known glucose-6-phosphate dehydrogenase (G6PD) deficiency;

• Known sickle cell anemia

• Pregnancy or breastfeeding;

• Known allergy to vitamin C;

• Known kidney stones within the past 1 year;

• Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;

• Expected death or withdrawal of life-sustaining treatments within 48 hours;

• Previously enrolled in this study;

• Previously enrolled in a trial for which co-enrolment is not allowed (co- enrolment to be determined case by case).

The trial has broad eligibility criteria and includes all COVID-19 patients admitted to the hospital (e.g. hospital ward or the intensive care unit) who are not receiving vasopressors.